Alto Neuroscience (NYSE:ANRO) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Key Points

• Alto Neuroscience reported a quarterly loss of $0.54 per share, beating analysts’ estimate of a $0.67 loss by $0.13.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $37.88; ratings range from Buy to Sell.
• Shares rose 3.4% to $28.75 in Tuesday trading. CFO Nicholas Smith also sold 24,056 shares, halving his direct stake.

Alto Neuroscience (NYSE:ANRO - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.13, FiscalAI reports.

Alto Neuroscience Trading Up 3.4%

ANRO stock traded up $0.95 during trading on Tuesday, reaching $28.75. 515,791 shares of the stock traded hands, compared to its average volume of 430,120. The firm has a market capitalization of $1.13 billion, a PE ratio of -11.88 and a beta of 1.42. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85. Alto Neuroscience has a 52-week low of $10.80 and a 52-week high of $37.48. The business's 50 day moving average price is $26.84 and its 200-day moving average price is $24.37.

Analyst Ratings Changes

Several brokerages recently issued reports on ANRO. Weiss Ratings reissued a "sell (d-)" rating on shares of Alto Neuroscience in a research note on Tuesday, October 27th. Zacks Research raised shares of Alto Neuroscience from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 20th. Wall Street Zen downgraded Alto Neuroscience from a "hold" rating to a "sell" rating in a report on Saturday, September 12th. HC Wainwright increased their price target on Alto Neuroscience from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, October 19th. Finally, Wedbush raised their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $37.88.

Insider Transactions at Alto Neuroscience

In related news, CFO Nicholas Smith sold 24,056 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $25.82, for a total value of $621,125.92. Following the completion of the sale, the chief financial officer directly owned 24,060 shares in the company, valued at approximately $621,229.20. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.25% of the company's stock.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto's approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.